Work

Supplementary Table S9 from Targeting Fibroblast Activation Protein with [177Lu]Lu-FAP-2286 in Patients with Advanced Solid Tumors in the Phase I LuMIERE Trial

Year: 2026

Type: supplementary-materials

Abstract: Table S9. Dosimetry of 177Lu-FAP-2286 in Cycle 1.

DOI: 10.1158/1078-0432.33403131

Authors: Jonathan McConathy, Vadim S. Koshkin, Yusuf Menda, Jordi Rodon, Ajit H. Goenka, Ryan H. Moy, Sophie Morse, Arnaud Demange, Lars Blumenstein, Burcu Babaoglan, Paola Aimone, Thomas A. Hope

Language: English

Topic: Radiopharmaceutical Chemistry and Applications

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W7204901875

Cites:

Cited by:

Related to: 10